BioBucks • Tracker
Biotech Venture Funding Tracker 2026
Private financings — Company, date, round, investors, therapeutic area, and a one-line “what they do.”
Last updated: 21 Jan 2026
Want the stay up to date as deals land?
We also publish a free daily newsletter with biotech dealflow + news + market tape in 5 mins — join 2,000+ VC, BD&L, and public biotech investors.
See past issues and join here →
January 2026
Infinitopes
Seed Extension
Date: 21-Jan-2026
|
Size: US$35M
|
Therapeutic area: Oncology (cancer vaccines / immuno-oncology)
Investors: Co-led Octopus Ventures, Amplify Bio; new Macmillan Cancer Support; existing Cancer Research Horizons, Manta Ray Ventures
What they do: Clinical-stage precision cancer vaccine company advancing ITOP1 to prevent recurrence in oesophageal cancer, enabled by its antigen discovery platform.
Think Bioscience
Series A
Date: 20-Jan-2026
|
Size: US$55M
|
Therapeutic area: Rare disease / small-molecule discovery
Investors: Led Regeneron Ventures, Innovation Endeavors, Janus Henderson Investors; participation T.A. Springer, CE-Ventures, MBX Capital, YK Bioventures; returning AV8 Ventures, CU Innovations, Buff Gold Ventures
What they do: Uses synthetic biology to uncover new "footholds" on hard targets for small-molecule drugging; lead program targets mutants driving Noonan syndrome.
Exciva
Series B
Date: 20-Jan-2026
|
Size: €51M
|
Therapeutic area: Neuropsychiatry
Investors: Co-led EQT Life Sciences (LSP Dementia Fund), Gimv; participation Fountain Healthcare Partners, LifeArc Ventures, Carma Fund, Modi Ventures, Andera Partners, LBBW
What they do: Clinical-stage neuropsychiatry company advancing Deraphan into Phase 2 for agitation associated with Alzheimer’s disease.
Caldera Therapeutics
Series A
Date: 14-Jan-2026
|
Size: US$112.5M
|
Therapeutic area: Immunology / Inflammation (IBD)
Investors: Founding Atlas Venture, LifeArc Ventures (LAV), venBio; A-1 led by Omega Funds; new Wellington Management, Janus Henderson Investors
What they do: Developing CLD-423, a first-in-class bispecific targeting IL-23p19 and TL1A for IBD and other inflammatory diseases.
Proxima
Seed
Date: 13-Jan-2026
|
Size: US$80M
|
Therapeutic area: Platform (AI drug discovery)
Investors: DCVC; NVentures (NVIDIA); Braidwell; Roivant; AIX Ventures; Yosemite; Magnetic; Alexandria Venture Investments; Modi Ventures (+ others)
What they do: AI-native drug discovery company (rebranded from VantAI) building a data + ML stack for proximity-based medicines that modulate protein–protein interactions (molecular glues / PROTAC-superset).
Cytotheryx
Series A
Date: 12-Jan-2026
|
Size: US$60M
|
Therapeutic area: Hepatology / Cell therapy
Investors: Ouroboros Family Founders Fund
What they do: Liver-focused cell therapy platform enabling scalable, functional human hepatocytes for multiple applications (e.g., bioartificial liver support and liver cell transplantation concepts).
Juvena Therapeutics
Series B
Date: 12-Jan-2026
|
Size: US$33.5M
|
Therapeutic area: Regenerative medicine (neuromuscular / age-related disease)
Investors: Led Bison Ventures; participation Eli Lilly and Company, Jefferson Life Sciences; existing Mubadala Capital, Manta Ray
What they do: AI-enabled regenerative biologics company advancing JUV-161, a muscle-regenerating biologic in Phase 1 for myopathic muscle degeneration.
Kinaset Therapeutics
Series B
Date: 10-Jan-2026
|
Size: US$103M
|
Therapeutic area: Respiratory / Immunology (asthma)
Investors: RA Capital; Forge Life Science Partners; EQT Life Sciences; Vivo; Schroders; Willett; Pictet; Sixty Degree; existing Atlas; 5AM; Gimv
What they do: Developing frevecitinib, an inhaled therapy for severe inflammatory respiratory disease, positioned to help non-eosinophilic asthma patients who lack good options.